[{"uuid": "866f7d8a-4e7b-3569-9ce4-d0caff0d1b5c", "title": "Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/amylyx-pharmaceuticals-amlx-upgraded-buy-170011253.html", "providerPublishTime": 1738342811, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/t6.OdXEVKQihFo9otNenfg--~B/aD01NjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9", "width": 900, "height": 565, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/k5cTNiJKtV5aggvBgwLXAQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AMLX"]}, {"uuid": "0d8e8d28-a5a4-3a9c-adf9-c3bf01f8adff", "title": "Amylyx Pharmaceuticals Says FDA Lifts Clinical Hold on Phase 1 ALS Study", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/amylyx-pharmaceuticals-says-fda-lifts-142857851.html", "providerPublishTime": 1737469737, "type": "STORY", "relatedTickers": ["AMLX"]}, {"uuid": "ad821f48-0452-3a00-be9f-a4867e96b69a", "title": "Intellia makes progress on HAE study; 2 more China drug deals", "publisher": "BioPharma Dive", "link": "https://finance.yahoo.com/m/ad821f48-0452-3a00-be9f-a4867e96b69a/intellia-makes-progress-on.html", "providerPublishTime": 1737540000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/H45ciFL01k8pIJfsr8ZYEA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259", "width": 1600, "height": 900, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/m8gMMn1cTlFUNNLyoWoNVA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["NTLA", "AVBP", "AMLX", "ATRA", "^YH206"]}, {"uuid": "e1aae072-8c42-30d4-a863-169574ca607e", "title": "Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/amylyx-pharmaceuticals-announces-fda-lifted-140000610.html", "providerPublishTime": 1737468000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/qXrVh5ArdxOf1v1lk1._eg--~B/aD01ODg7dz0yNTE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cf0b75156908e29fe9bb8e7c744ee249", "width": 2517, "height": 588, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/rVMsW_Xmf2R8PdtB3AO_nw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cf0b75156908e29fe9bb8e7c744ee249", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AMLX"]}, {"uuid": "0adea8d3-3e6d-3705-8b51-cc2bbb0e3aac", "title": "Amylyx Pharmaceuticals Prices $60 Million Common Stock Offering", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/amylyx-pharmaceuticals-prices-60-million-141058195.html", "providerPublishTime": 1736518258, "type": "STORY", "relatedTickers": ["AMLX"]}, {"uuid": "775fcac0-9afc-39a2-a212-7c6e38f67e36", "title": "Amylyx Pharmaceuticals Launches Stock Offering", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/amylyx-pharmaceuticals-launches-stock-offering-093119922.html", "providerPublishTime": 1736501479, "type": "STORY", "relatedTickers": ["AMLX"]}, {"uuid": "80ea21dd-7091-3076-b8e1-b4abe215ab90", "title": "Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/amylyx-pharmaceuticals-announces-pricing-public-132600072.html", "providerPublishTime": 1736515560, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/k.nL5Q3nUw0nYBmF5w6wxw--~B/aD01ODg7dz0yNTE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/e2d7bb6bb8ed1a58aa301ff7210c2ae8", "width": 2517, "height": 588, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Kueka39LiQ_B5T8DGF8PQA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/e2d7bb6bb8ed1a58aa301ff7210c2ae8", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AMLX"]}, {"uuid": "83a8cc9a-c368-3f01-96b3-260f9a155acf", "title": "Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/amylyx-pharmaceuticals-announces-proposed-public-003000239.html", "providerPublishTime": 1736469000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Qix9OPOmS_J5fTe9Zj4oIg--~B/aD01ODg7dz0yNTE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a8a78cc6a36929ea4355ffc3f01dfbde", "width": 2517, "height": 588, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/5oHaAs8HWj8ZTTz0_WQORQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a8a78cc6a36929ea4355ffc3f01dfbde", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AMLX"]}, {"uuid": "b22d548a-765e-36d0-8f2f-4fb7dc7d61be", "title": "Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/amylyx-pharmaceuticals-appoints-dan-monahan-140000570.html", "providerPublishTime": 1736172000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/.swABhjgf8wmiqqZ3WuIHg--~B/aD01ODg7dz0yNTE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cb2ad4dcbcf241eafb2d3e0ca6497de4", "width": 2517, "height": 588, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/xl22KIhbVOYzszhOy4vawA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cb2ad4dcbcf241eafb2d3e0ca6497de4", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AMLX"]}, {"uuid": "16140329-d139-3475-8a7b-256e4f26d67e", "title": "Cerus And 2 Other US Penny Stocks With Promising Potential", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/cerus-2-other-us-penny-170754442.html", "providerPublishTime": 1736183274, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/S0lfvVFvT2zEUqilo.yhog--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2260c3158cb31199a7e2c221586ac549", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/X53cYHXNW8ncY2zrbMqFSA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2260c3158cb31199a7e2c221586ac549", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CERS", "DC", "DC-WT", "AMLX"]}, {"uuid": "16f45348-fe92-3a4b-bd78-28033b131c0e", "title": "Why Is Amylyx Pharmaceuticals (AMLX) Among the Best Biotech Penny Stocks to Invest in Now?", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/why-amylyx-pharmaceuticals-amlx-among-195244205.html", "providerPublishTime": 1735588364, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/J8IuZZrNdTIBhY5oZdg2xA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/d91cbc81ed66af46e27858c4a2930253", "width": 1456, "height": 816, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Nc7PLtyCuc_HfSWxAvKVvA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/d91cbc81ed66af46e27858c4a2930253", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AMLX"]}, {"uuid": "56039f7c-cf45-37c4-ae4e-ec32c760ace2", "title": "Amylyx Pharmaceuticals, Gubra Collaborate on GLP-1 Therapy Development", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/amylyx-pharmaceuticals-gubra-collaborate-glp-201403499.html", "providerPublishTime": 1735589643, "type": "STORY", "relatedTickers": ["AMLX"]}, {"uuid": "552cca90-3a37-39ae-b33f-d2e74c4305a6", "title": "Amylyx announces design of LUCIDITY clinical trial", "publisher": "TipRanks", "link": "https://finance.yahoo.com/news/amylyx-announces-design-lucidity-clinical-123534925.html", "providerPublishTime": 1733402134, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/ShAwIQ85SkA_hiR9ajTS9A--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/bd23518bddbecaa2e26b66cd7da7f21e", "width": 192, "height": 192, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/vx7Ki8YEnr5LZSuutkC7jQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/bd23518bddbecaa2e26b66cd7da7f21e", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AMLX"]}, {"uuid": "a7faffde-eb7b-38be-a36f-8b32a484245b", "title": "Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...", "publisher": "GuruFocus.com", "link": "https://finance.yahoo.com/news/amylyx-pharmaceuticals-inc-amlx-q3-071113392.html", "providerPublishTime": 1731049873, "type": "STORY", "relatedTickers": ["AMLX"]}, {"uuid": "eaebafeb-2df8-3204-8a1d-2e10dab27102", "title": "Amylyx Pharmaceuticals Third Quarter 2024 Earnings: US$1.07 loss per share (vs US$0.31 profit in 3Q 2023)", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/amylyx-pharmaceuticals-third-quarter-2024-145628080.html", "providerPublishTime": 1731164188, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c", "width": 945, "height": 636, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/NamfX5LEtyScIu4YmRG2hg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AMLX"]}, {"uuid": "ffc11800-387f-3864-83e3-9c5e483b9949", "title": "Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/amylyx-pharmaceuticals-announces-pivotal-phase-123000881.html", "providerPublishTime": 1733315400, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Tq26T3YokwfzoTTSw8FffQ--~B/aD01ODg7dz0yNTE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/1ead0430340637e5983c36ade7789984", "width": 2517, "height": 588, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/2EYsrWWIJP3asDfmFYQU.w--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/1ead0430340637e5983c36ade7789984", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AMLX"]}, {"uuid": "9af415d7-1c4e-348a-8fc1-d04f10c9f676", "title": "Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/amylyx-pharmaceuticals-reports-third-quarter-120000575.html", "providerPublishTime": 1730980800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/R6mWST0Uiw5I72IajriwwA--~B/aD01ODg7dz0yNTE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/570450fc193c48c5d1e5b851819c3ede", "width": 2517, "height": 588, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/dCfX5fkwT3sYouCEHag4GQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/570450fc193c48c5d1e5b851819c3ede", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AMLX"]}, {"uuid": "456aecb4-12b1-3760-953d-d45e0e36b7c9", "title": "Baird Upgrades Amylyx Pharmaceuticals to Outperform From Neutral, Adjusts Price Target to $11 From $3", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/baird-upgrades-amylyx-pharmaceuticals-outperform-123948314.html", "providerPublishTime": 1731933588, "type": "STORY", "relatedTickers": ["AMLX"]}, {"uuid": "0c9a5db4-fb52-32c0-9489-48624b058830", "title": "Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/amylyx-pharmaceuticals-present-7th-annual-140000031.html", "providerPublishTime": 1732716000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/G9TEU4A0M.u4fFNBymrg3A--~B/aD01ODg7dz0yNTE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/07a59c3a37255a7ea2f3dcbb46c3f3a7", "width": 2517, "height": 588, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/SYqZCNLJT4ZRn7RC.96WwA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/07a59c3a37255a7ea2f3dcbb46c3f3a7", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AMLX"]}, {"uuid": "8e8c6bf1-1d37-342c-a1d7-85dda6b5f4dc", "title": "Q3 2024 Amylyx Pharmaceuticals Inc Earnings Call", "publisher": "Thomson Reuters StreetEvents", "link": "https://finance.yahoo.com/news/q3-2024-amylyx-pharmaceuticals-inc-063341962.html", "providerPublishTime": 1731047621, "type": "STORY", "relatedTickers": ["AMLX"]}]